XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Recruiting · NCT06959641 · Registry updated 2026-06-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid tumor | Recruiting | Phase 2 | 2026-06-26 | NCT06959641 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jochen Lorch | 1 |
| National Cancer Institute (NCI) | 3015 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Harbor-UCLA Medical Center | Torrance | United States | 10 |
| Northwestern University | Chicago | United States | 727 |